Name: Antibody Drug Conjugates: Design, Discovery, and Development (en Inglés)
SKU: 66555721
Price: 366633.00 COP
Availability: InStock
Author: Gukasyan, Hovhannes J.; Kulkarni, Ashutosh
ISBN: 9783031893186

portada Antibody Drug Conjugates: Design, Discovery, and Development (en Inglés)

Antibody Drug Conjugates: Design, Discovery, and Development (en Inglés)

Formato

Libro Físico

Editorial

Springer

Autor

Gukasyan, Hovhannes J.; Kulkarni, Ashutosh

Idioma

Inglés

N° páginas

232

Encuadernación

Tapa Dura

Dimensiones

23.7x16.3x2 cm

ISBN13

9783031893186

Antibody Drug Conjugates: Design, Discovery, and Development (en Inglés)

Gukasyan, Hovhannes J.; Kulkarni, Ashutosh (Autor) · Springer · Tapa Dura

Libro Nuevo Importado

Envío: 18 a 24 días háb.

$ 733.265$ 366.633

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 366.633

¡Envío Gratis! Llega entre el 11 Sep y el 22 Sep a Bogota, Cundinamarca. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Antibody Drug Conjugates: Design, Discovery, and Development (en Inglés)"

This volume provides a comprehensive recapitulation of structure-activity relationship (SAR) from a mechanism of action point of view for this unique therapeutic modality, in a largely disease agnostic manner. From a disease biology and pharmacology perspective, the cellular target and drug-conjugate selection, considerations on liker -chemistry and -antibody ratio, and formulation science and technology, to get from bench to bedside (i.e. from a laboratory to the systemic circulation in a patient). The book also provides an understanding around target binding and drug/"payload" release mechanisms. Furthermore, pharmacokinetic and safety pharmacological aspects from a regulatory and clinical perspective are discussed, along with current chemistry, manufacturing, controls guidance and emerging novel delivery devices or technologies. The key differentiation in Antibody Drug Conjugates is the clinical and development discussion, that offers pragmatic considerations in medical product development, IP, regulatory considerations, among others. Furthermore, we discuss the topic as a platform, in a disease agnostic manner.